Enanta Pharmaceuticals Inc (ENTA)

[willyw]

More G-3 data from AASLD
(note this contains verification that dosing was be 3 pills (3- 100mg/40/mg pills)

SURVEYOR-II, PART 3: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR (ABT-493/ABT-530) IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION WITH PRIOR TREATMENT EXPERIENCE AND/OR CIRRHOSIS
http://www.natap.org/2016/AASLD/AASLD_20.htm


compare to Gilead's G-3 Epclusa data

High Efficacy of Sofosbuvir/Velpatasvir In HCV Genotypes 1-6 Infected Patients With Cirrhosis: Pooled Data From the ASTRAL 1, 2 and 3 Trials
http://natap.org/2015/hepDART/hepDART_09.htm


It is a little complicated (or daring leap) since I don't know how each defined treatment experience and what percentage was interferon based versus DAA experienced and differing types of exposures and resultant RAVs

Per this link you can see about past mid point is the table
"SVR by Treatment History in Patients with Cirrhosis"
which shows that Sof/Vel in G-3 resulted in cure rates of;

93% in treatment naive patients w/ cirrhosis (40/43)

89% in treatment experienced patients w/ cirrhosis (33/37)

==================

Compare to Abbvies G/P 2nd gen from above link;
http://www.natap.org/2016/AASLD/AASLD_20.htm

Phase 2 data ("Background and objectives table")

100% SVR in TX naive patients w/ cirrhosis. 12 wk (24/24)

92% SVR in TX experienced patients w/ cirrhosis 12 wk (22/24)

Surveyor part 3

98% SVR in 12 wk tx naive patients w/ cirrhosis (39/40)

91% SVR in 12 wk treatment naive patients w/ cirrhosis (20/22)

96% 16 week treatment experienced w/o cirrhosis (21/22)

96% 16 week treatment experienced with cirrhosis (45/47)

For me Abbvie data looks very competitive..... superior in G-3 to Gilead's

Adding 4 more to treat the hardest to treat group doesn't seem to be excessive for a 16 week total.

I still admit it would be good to see definitions and percentages of treatment experienced since it will make a great difference to results. This seems to be what I could find, however.

This kind of comparison is important since these are the two front line programs Gilead's Epclusa vrs Abbvies G/P 2nd gen.

In the United states this is where the majority of business should be; in G1 primarily, but also in G-3 since it is a previously harder to treat genotype and prior to Epclusa very very expensive, and with some warehousing of patients. (in USA and world wide)